Evidence map›Paper›PMID 41291882›Full record

ArticleOrphanet journal of rare diseases2025

Human, economic, and social impact of lysosomal storage diseases.

Eduardo Brignani, María José de Castro-López, Antonio Gonzalez-Meneses, Montserrat Morales, Guillem Pintos-Morell, José Luis Poveda, Imma Vilalta, Jordi Cruz, Gabriel Fernando Ballester-Lozano, Héctor David de Paz

Abstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Eduardo BrignaniFederación Española de Enfermedades Raras, Barcelona, Spain.
María José de Castro-LópezManchester University NHS Foundation Trust, Manchester, UK.
Antonio Gonzalez-MenesesHospital Universitario Virgen del Rocío, Seville, Spain.
Montserrat MoralesHospital Universitario 12 de Octubre, Madrid, Spain.
Guillem Pintos-MorellVall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
José Luis PovedaHospital Universitario y Politécnico La Fe, Valencia, Spain.
Imma VilaltaHospital Sant Joan de Déu, Barcelona, Spain.
Jordi CruzAsociación MPS-Lisosomales, Avda. Barcelona nº 174, 1º 2a, Igualada, Barcelona, 08700, Spain. jordi.cruz@mpslisosomales.org.
Gabriel Fernando Ballester-LozanoOutcomes Research Department, Outcomes'10, S.L., Castellón de la Plana, Spain.
Héctor David de PazOutcomes Research Department, Outcomes'10, S.L., Castellón de la Plana, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLysosomal storage disorders (LSDs) are a group of rare metabolic conditions caused by enzyme deficiencies, leading to the accumulation of macromolecules within lysosomes. These disorders significantly impact patients' quality of life (QoL) and impose substantial financial burdens on families and healthcare systems. This study aimed to evaluate the daily life impact and economic burden of LSDs on patients, caregivers, the Spanish Health System (SHS), and society.

methodsThis cross-sectional study used an ad hoc questionnaire targeting Spanish LSD patients and their caregivers. The questionnaire was based on a literature review and insights from patients, caregivers, and healthcare professionals (HCPs). Data were collected on sociodemographic characteristics, clinical variables, QoL, and economic costs. Caregivers provided responses on behalf of both themselves and the patients. Direct and indirect costs were assessed based on healthcare resource utilisation, productivity losses, and patient-incurred expenses.

resultsThe study included data on 86 patients, with 22 patients responding on their own behalf and 64 caregivers responding on behalf of themselves and their patient. Twelve different LSDs were identified, with Sanfilippo (22.1%) and Fabry (18.1%) being the most prevalent. The mean age at diagnosis was 9.9 years, with an average diagnostic delay of 4.3 years. Patients required an average of 107.8 medical visits per year, many of which were out-of-pocket, particularly for physiotherapy (28.6 visits/year) and psychological services. The total annual cost per patient was €228,232.60, with direct costs to the SHS accounting for 81.4% of this amount. Indirect costs, primarily due to informal caregiving and productivity losses, represented 15.9%. Families bore an average annual cost of €6,170.20, mainly for formal care and non-covered medical expenses. Clinically, 29.1% of patients had severe-to-profound functional limitations, and 31.4% had cognitive limitations, significantly affecting their daily activities, mobility, and emotional well-being.

conclusionsLSDs impose a substantial economic and social burden on patients and their families, with high healthcare costs and significant productivity losses. The study underscores the need for comprehensive support strategies addressing both economic and social challenges faced by affected families. Future research should explore country-specific economic impacts and develop policies to mitigate the financial strain on these families.

Indexed as

Lysosomal Storage DiseasesAdolescentAdultCaregiversChildChild, PreschoolCost of IllnessCross-Sectional StudiesFemaleHumansMaleMiddle AgedQuality of LifeSurveys and QuestionnairesYoung AdultCaregiver burdenEconomic impactHealthcare costsLysosomal storage disordersPatient burdenQuality of life

Identifiers

PMID41291882
PMCPMC12645673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.